Cisplatin-Induced Kidney Injury: Delivering the Goods

Affiliations

Editorial

Joshua N Curry et al. J Am Soc Nephrol. 2022 Feb.

. 2022 Feb;33(2):255-256.

doi: 10.1681/ASN.2021121591.

¹ Division of Nephrology and Hypertension, Oregon Health and Science University, Portland, Oregon.

No abstract available

Keywords: acute kidney injury; chronic kidney disease; cisplatin nephrotoxicity; renalase.

Comment on

Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.
Guo X, Xu L, Velazquez H, Chen TM, Williams RM, Heller DA, Burtness B, Safirstein R, Desir GV. Guo X, et al. J Am Soc Nephrol. 2022 Feb;33(2):342-356. doi: 10.1681/ASN.2021040439. Epub 2021 Dec 17. J Am Soc Nephrol. 2022. PMID: 34921111 Free PMC article.

1. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD: Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11: 1173–1179, 2016 - PMC - PubMed
1. Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. : Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One 9: e101902, 2014 - PMC - PubMed
1. McSweeney KR, Gadanec LK, Qaradakhi T, Ali BA, Zulli A, Apostolopoulos V: Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers (Basel) 13: 1572, 2021 - PMC - PubMed
1. Guo X, Xu L, Velazquez H, Chen T-M, Williams RM, Heller D, et al. : Kidney-targeted renalase agonist prevents cisplatin-induced chronic kidney disease by inhibiting regulated necrosis and inflammation. J Am Soc Nephrol 33: 342–356, 2022 - PMC - PubMed
1. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. : Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 115: 1275–1280, 2005 - PMC - PubMed